VTAK (Catheter Precision) Notes Receivable: $0.00 Mil (As of Mar. 2026)


VTAK Catheter Precision Inc VTAK
23 GF Score
Price $0.79
GF Value $1.71
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Catheter Precision Notes Receivable?

Catheter Precision VTAK -8.67% 23 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates VTAK with a GF Score™ of 23/100 and a GF Value™ of $1.71 (Possible Value Trap). The stock has 7 warning signs investors should review.

Catheter Precision's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Catheter Precision Notes Receivable Related Terms

Catheter Precision Notes Receivable Historical Data

* Premium members only.

The historical data trend for Catheter Precision's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Catheter Precision Notes Receivable Chart

Catheter Precision Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Catheter Precision Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
VTAK
23GF Score
Catheter Precision Inc VTAK
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Catheter Precision Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Catheter Precision (VTAK) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Catheter Precision and its competitors.
Is Catheter Precision's Notes Receivable too high?
Catheter Precision's current Notes Receivable is $0.00 Mil. Overall, Catheter Precision has a GF Score™ of 23/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Catheter Precision's Notes Receivable compare to ALURD and BJDX?
Catheter Precision's Notes Receivable of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Catheter Precision and its competitors. Catheter Precision's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catheter Precision stock overvalued right now?
Based on GuruFocus' analysis, Catheter Precision (VTAK) is currently considered Possible Value Trap. The stock's GF Value™ is $1.71, compared to a current price of $0.79 — trading 53.8% below its estimated fair value. The current Notes Receivable is $0.00 Mil. Catheter Precision's overall GF Score™ is 23/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Catheter Precision (VTAK), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Catheter Precision (VTAK) Overvalued in 2026?

Based on GuruFocus' analysis, Catheter Precision stock appears to be undervalued. The current stock price of $0.79 is trading 53.8% below its estimated GF Value™ of $1.71. GuruFocus considers Catheter Precision to be Possible Value Trap.

Key valuation signals for VTAK:

  • Notes Receivable: $0.00 Mil
  • GF Value™: $1.71 vs. price of $0.79 (53.8% below fair value)
  • GF Score™: 23/100 with 7 warning signs

No single metric tells the full story. See the VTAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Catheter Precision Business Description

Address 1670 Highway 160 West, Suite 205, Fort Mill, SC, USA, 29708
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
23GF Score

Get the complete analysis for VTAK

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.79
Price
$1.71
GF Value